SC
LGND icon

Stephens Consulting’s Ligand Pharmaceuticals LGND Stock Holding History

Stephens Consulting’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$526 – 1624
2025
Q1 		$526 Buy
+5
New +$565 ﹤0.01% 910
2024
Q3 		– Sell
-24
Closed -$2.02K – 595
2024
Q2 		$2.02K Buy
+24
New +$1.91K ﹤0.01% 510

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's LGND Position: Q2 2025 in Review

Stephens Consulting sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 5 shares — an estimated $526 sold.

Stephens Consulting first reported a position in LGND in Q2 2024 and held it in 2 quarters. The position peaked at $2.02K in Q2 2024. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Stephens Consulting reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 5 Ligand Pharmaceuticals shares in Q2 2025, an estimated $526.
  • Stephens Consulting first reported a position in Ligand Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Ligand Pharmaceuticals position peaked at $2.02K in Q2 2024.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.